Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;95(7):592-5.
doi: 10.1111/j.1349-7006.2004.tb02492.x.

Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma

Affiliations

Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma

Satoshi Yamamoto et al. Cancer Sci. 2004 Jul.

Abstract

Although hepatitis C virus (HCV)-related cirrhosis has been suggested as a risk factor for intrahepatic cholangiocarcinoma (ICC), few sizeable studies have tested this hypothesis. We investigated ICC risk factors, with special reference to HCV infection. We conducted a hospital-based case-control study including 50 ICC patients and 205 other surgical patients without primary liver cancer. HCV seropositivity was detected in 36% of ICC patients and 3% of controls. By univariate analysis, the odds ratio (OR) for association of anti-HCV antibodies with development was 16.87 (95% confidence interval (CI), 5.69 to 50.00). History of blood transfusion or diabetes mellitus, elevated serum total bilirubin, elevated aspartate aminotransferase and alanine aminotransferase, decreased serum albumin and decreased platelet count were identified as other possible ICC risk factors. By multivariate analysis, anti-HCV antibodies (adjusted OR, 6.02; 95% CI, 1.51 to 24.1), elevated alanine aminotransferase, decreased serum albumin, and decreased platelet count were found to be independent risk factors for ICC development. As liver status worsened, the adjusted OR for ICC tended to increase. HCV infection is a likely etiology of ICC in Japan.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Yamamoto M, Takasaki K, Nakano M, Saito A. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998; 82: 2145–9. - PubMed
    1. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada H. Incidence of primary cholangiocel‐luar carcinoma of the liver in Japanese patients with hepatitis C virus‐related cirrhosis. Cancer 2000; 88: 2471–7. - PubMed
    1. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology. J Gastroenterol Hepatol 2002; 17: 1049–55. - PubMed
    1. Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995; 19: 637–41. - PubMed
    1. Tomimatsu M, Ishiguro N, Taniai M, Okuda H, Saito A, Obata H, Yamamoto M, Takasaki K, Nakano M. Hepatitis C virus antibody in patients with primary liver cancer(hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular‐cholangiocarcinoma)in Japan. Cancer 1993; 72: 683–8. - PubMed

MeSH terms

Substances